Information posted June 26, 2020
Effective September 8, 2020, the Vendor Drug Program (VDP) will implement the clinical prior authorization criteria for Oxbryta (voxelotor) for traditional Medicaid. The Texas Drug Utilization Review Board approved Oxbryta as part of the Sickle Cell Disease Agents criteria at its January 2020 meeting.
This prior authorization is optional for Medicaid managed care. The Pharmacy Clinical Prior Authorization Assistance Chart shows the prior authorization each managed care organization uses and how those authorizations relate to traditional Medicaid claim processing. This chart is updated quarterly and available on the VDP website.
Contact email@example.com for more information.